MetaCap

CalciMedica (CALC) vs Chemomab Therapeutics (CMMB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Chemomab Therapeutics (CMMB) has outperformed CalciMedica (CALC) over the past year, losing 53.0% versus a loss of 92.3%. Chemomab Therapeutics is the larger company by market cap ($9.6 million vs $8.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CALC-92.34%CMMB-52.96%
+115%+6%-104%
Nov 21, 20251 yearNov 20, 2026
CALC-94.99%CMMB-82.60%
+40%-31%-102%
Jun 12, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CALC versus CMMB key metrics
MetricCALCCMMB
Share price$1.26$1.19
Market cap$8.69M$9.58M
1-day change+7.69%+4.39%
YTD return-96.18%-27.88%
1-year return-92.34%-52.96%
5-year return—-96.65%
EPS (TTM)$-4.41$-1.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-29.56M$-8.99M
52-week high$36.00$2.99
52-week low$1.00$0.92
Distance from 52-week high-96.50%-60.20%
Analyst consensusnonenone
Avg. price target upside+3868.25%+320.17%
Average volume80.15K102.39K
Shares outstanding6.90M8.05M
Employees15—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CMMB has outperformed CALC by 39.4 percentage points over the past year.

About CalciMedica

CALC stock →

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Chemomab Therapeutics

CMMB stock →

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.

Health Care · Biotechnology: Pharmaceutical Preparations

CALC vs CMMB FAQ

Which is bigger, CalciMedica or Chemomab Therapeutics?

Chemomab Therapeutics (CMMB) is larger, with a market capitalization of $9.58M compared with $8.69M for CalciMedica (CALC).

Which stock has performed better over the past year, CALC or CMMB?

CMMB returned -52.96% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.

Are CalciMedica and Chemomab Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons